Published August 3, 2015 | Version v1
Journal article Open

TSPO as a target for glioblastoma therapeutics.

  • 1. Faculty of Health Sciences, The University of Sydney, Sydney, NSW 2006, Australia
  • 2. Faculty of Health Sciences, The University of Sydney, Sydney, NSW 2006, Australia and School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia

Description

The translocator protein (TSPO) is an 18-kDa five-transmembrane protein, which is primarily found in the outer mitochondrial membrane. Levels of this protein are up-regulated in the most aggressive and common glioma, glioblastoma multiforme (GM). Levels of TSPO also correlate with GM clinical outcome, suggesting that TSPO may be a novel GM diagnostic imaging agent. Therapeutically, targeting the TSPO may provide a mechanism to abrogate the apoptotic-resistant, invasive and aggressive nature of GM and may also provide a way of targeting other anti-cancer treatments to GM sites. This review highlights recent progress in research on TSPO-based diagnostic imaging and therapeutics for GM.

Files

Werry_BiochemSocTrans_2015-P19.pdf

Files (232.4 kB)

Name Size Download all
md5:801ac028241fb0d61774f886bee243f8
232.4 kB Preview Download

Additional details

Funding

INMIND – Imaging of Neuroinflammation in Neurodegenerative Diseases 278850
European Commission